|
|
 |
|
Viewing report
|
|
|
|
The CNS Market Outlook to 2010
Business Insights, Oct 2005
Maximize future market opportunity with the help of this NEW report...
The traditional markets of depression and schizophrenia will see further product launches in the next few years, however many of the major players are set to perform disappointingly in these traditional markets due to increasing pricing pressure from generic competition and limited differentiation among new medicines.
The new report 'The CNS Market Outlook to 2010' provides detailed analysis on 7 key indications in the CNS Market, identifying growth brands, leading companies and epidemiology and product sales forecasts over the period 2005-2010. The 6-year forecasts detailed in this report will enable you to evaluate changes in the competitive positions of leading companies in the CNS market and ensure your R&D pipeline is aligned with future market opportunity to sustain revenue growth.
This report will enable you to benchmark the strategies behind the market-leading products of today and identify which products will be best positioned for growth over the period 2005-2010.
Key statistics and analysis detailed in this report:
- Company analysis and market share of the top players in the CNS market including:
- Pfizer, Johnson & Johnson, GlaxoSmithKline, Wyeth, AstraZeneca, and Sanofi-Aventis
- Epidemiological analysis and forecasts in 7 key indications in the CNS market: Alzheimer's disease, depression, epilepsy, migraine, pain, Parkinson's disease and schizophrenia
- Detailed analysis and sales forecasts of high potential products in the pipelines of the major players
The answers to your questions
- What will be the major growth indications in the CNS market over the period 2005-2010?
- Which companies were the winners and losers in the CNS market in 2004?
- How have recent major launches from Pfizer, Forest, Lilly and Bristol-Myers Squibb performed?
- Which products will be impacted by generic competitors over the period 2005-2010?
- Which pipeline products will be the growth drivers of the future and why?
- What will the competitive landscape in depression, schizophrenia, epilepsy, migraine, Parkinson's disease, Alzheimers disease and pain look like in 2010?
Why you should order your copy today
- Save time and money in research with the report's coverage of the 7 largest indications in the CNS market, the 7 largest geographic pharmaceutical markets and the 8 largest companies active in the CNS market today.
- Understand now how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in CNS marketplace.
- Discover which CNS indications have the greatest potential to provide franchise growth, and how the pharmaceutical industry is attempting to exploit these opportunities.
- Compare the franchises of key players in the CNS market across major indications, and understand how the market share of leading companies will change over the next 6 years.
- Use head-to-head comparisons of the CNS pipelines of the leading players to understand which companies will be competing in the key CNS indications over the next 6 years.
Companies mentioned:
- Johnson & Johnson
- Pfizer
- GlaxoSmithKline
- Lilly
- Sanofi-Aventis
- Wyeth
- AstraZeneca
- Forest Labs
|
|
|
|
